ExpreS2ion’s joint venture AdaptVac receives Eurostars grant to further support its HER2 vaccine project AV001

Hørsholm, Denmark, February 25, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that a consortium led by the company’s joint venture AdaptVac has been awarded a 0.6 MEUR Eurostars grant, of which AdaptVac directly receives 1.3 MDKK (1.8 MSEK). The grant will support pre-clinical safety and efficacy studies of AV001 (HER2-cVLP) in pet dogs with spontaneous cancer and non-human primates as part of the breast cancer vaccine clinical development program for AV001 (HER2-cVLP). ExpreS2ion expects to receive 0.7 MDKK (1.0 MSEK) from this grant.

The aim of the consortium project is to establish safety and immunogenicity in different in vivo models, further develop the production process and prepare for clinical development. The consortium project will therefore de-risk further development, making AV001 more attractive to partnering or licensing within both the veterinary and human vaccine market. Reimbursement will be made on a quarterly basis in connection to expenses within the project.

ExpreS2ion’s CEO Bent Frandsen comments:

“This grant again demonstrates AdaptVac’s ability to obtain soft funding from grant awards. We appreciate working closely with the AdaptVac team on this project as a consortium member. Importantly, this funding strengthens the AV001 (HER2-cVLP) program through preclinical and manufacturing development towards clinical studies”.

The consortium consists of three Danish partners: AdaptVac ApS, ExpreS2ion Biotechnologies ApS and University of Copenhagen, and two Dutch partners: LiteVax B.V. and the Biomedical Primate Research Centre (BPRC).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telephone: +46 70 755 95 51

E-mail: ca@skmg.se

For further information about ExpreS2ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO      

Telephone: +45 4256 6869

E-mail: buf@expres2ionbio.com

 

This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on February 25, 2020.

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.

 

About Us

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.

Subscribe